Akebia Therapeutics Stock Price - AKBA

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 3.46 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Akebia Therapeutics Inc AKBA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.12 3.59% 3.46 3.898 3.3899 3.59 3.34 17:54:10
Bid Price Ask Price Spread Spread % News
3.46 3.52 0.06 1.7% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
11,532 2,994,893 $ 3.51 $ 10,506,551 816,808 2.99 - 11.50
Last Trade Time Type Quantity Stock Price Currency
16:00:22 14 $ 3.46 USD

Akebia Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 411.27M 118.86M $ -143.59M -2.47 -2.42 116.88M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 2.00 1.70%

more financials information »

Akebia Therapeutics News

Loading Messages....

Latest AKBA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AKBA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.263.8983.063.271,621,7350.206.13%
1 Month4.174.252.993.541,093,368-0.71-17.03%
3 Months4.345.772.994.06863,579-0.88-20.28%
6 Months5.455.772.994.22876,185-1.99-36.51%
1 Year6.9411.502.995.821,027,954-3.48-50.14%
3 Years8.9320.252.998.79654,520-5.47-61.25%
5 Years15.1020.252.998.96530,720-11.64-77.09%

Akebia Therapeutics Description

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Your Recent History
Akebia The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.